Two-compartment pharmacokinetic model of itraconazole after single oral dose administration – gender differences
Abstract
Background/Aim. Itraconazole (ICZ) is a widely used antifungal drug with hypervariable pharmacokinetics (PK), which is the result of the molecule’s nature itself, as well as the influence of multiple factors. One of the factors is gender, but its importance is not yet substantiated. The aim of the study was to examine the effect of gender on ICZ PK using a two-compartment model, obtained after a single oral dose of the drug, under fed conditions, in healthy participants of both genders. Methods. A previously conducted bioequivalence study of two pharmaceutical formulations of a 100 mg oral dose of ICZ in 38 healthy participants (22 men and 16 women) yielded 114 sets of ICZ plasma concentrations. Of these, 64 sets (40 from men and 24 from women) were analyzed in this study using Kinetica software as they fit the two-compartment model. ICZ plasma concentrations were determined by a previously validated liquid chromatographic method with mass spectrometric detection. Statistical analyses in SPSS included Mann-Whitney U and Fisher’s exact tests for group comparisons, along with Spearman’s correlation for parameter relationships. Results. Poorer ICZ absorption was observed in females compared to males, accompanied by differences in the drug’s distribution process between the central and peripheral compartments and vice versa. What’s more, there are also differences in ICZ elimination between genders, with it being more effective in women. This isn’t solely a result of a more prominent first-pass effect, but is also connected to the terminal phase of elimination after oral administration of the drug. Conclusion. The application of a two-compartment model for ICZ after its single oral dose administration under fed conditions in healthy research participants provided a more detailed insight into the variable PK of this drug, as well as into the existing gender-based differences.
References
Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46(3): 327–60.
Rogers D, Krysan D. Antifungal Agents. In: Brunton LL, Hilal-Dandan R, Knollmann BC, editors. Goodman and Gilman’s The pharmacological basis of therapeutics. 13th ed. New-York: McGraw-Hill Education; 2018. p. 1087–104.
Frazier WT, Santiago-Delgado ZM, Stupka KC 2nd. Onychomy-cosis: Rapid Evidence Review. Am Fam Physician 2021; 104(4): 359–67.
Armstrong-James D. Antifungal chemotherapies and immuno-therapies for the future. Parasite Immunol 2023; 45(2): e12960.
Hardin TC, Graybill JR, Fetchick R, Woestenborghs R, Rinaldi MG, Kuhn JG. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 1988; 32(9): 1310–3.
De Beule K, Van Gestel J. Pharmacology of itraconazole. Drugs 2001; 61 Suppl 1: 27–37.
Sweetman SC. Martindale: the complete drug reference. 36th ed. Book & CD-ROM Package. London: Pharmaceutical Press; 2009. p. 3712.
Abuhelwa AY, Mudge S, Hayes D, Uptona NR, Foster JRD. Pop-ulation in vitro-in vivo correlation model linking gastrointes-tinal transit time, pH, and pharmacokinetics. Itraconazole as model drug. Pharm Res 2016; 33(7): 1782–94.
Rowland M, Tozer T. Clinical Pharmacokinetics and pharmaco-dynamics: Concepts and Applications. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2011. p. 864.
Cross LJ, Bagg J, Oliver D, Warnock D. Serum itraconazole con-centrations and clinical responses in Candida-associated den-ture stomatitis patients treated with itraconazole solution and itraconazole capsules. J Antimicrob Chemother 2000; 45(1): 95–9.
Fagiolino P, González N, Vázquez M, Eiraldi R. Itraconazole bi-oequivalence revisited: Influence of gender on highly variable drugs. Open Drug Metab J 2007; 1: 7–13.
Thompson GR 3rd, Lewis P, Mudge S, Patterson TF, Burnett BP. Open-Label Crossover Oral Bioequivalence Pharmacokinetics Comparison for a 3-Day Loading Dose Regimen and 15-Day Steady-State Administration of SUBA-Itraconazole and Con-ventional Itraconazole Capsules in Healthy Adults. Antimi-crob Agents Chemother 2020; 64(8): e00400–20.
Heykants J, Van Peer A, Van de Velde V, Van Rooy P, Meulder-mans W, Lavrijsen K, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989; 32 Suppl 1: 67–87.
Prentice AG, Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemiother 2005; 56 Suppl 1: i17–22.
Bellmann R, Smuszkiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of pa-tients. Infection 2017; 45(6): 737–79.
European Medicines Agency. Guideline on the investigation of bioequivalence [Internet]. London: EMA; 2010 [cited 2023 Sep 29; accessed 2024 April 24]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf
Dragojević-Simić V, Kovačević A, Jaćević V, Rančić N, Djordjević S, Kilibarda V, et al. Bioequivalence study of two formulations of itraconazole 100 mg capsules in healthy volunteers under fed conditions: a randomized, three-period, reference-replicated, crossover study. Expert Opin Drug Metab Toxicol 2018; 14(9): 979–88.
Sweetman SC. Martindale: The Complete Drug Reference. 37th ed. London: Pharmaceutical Press; 2011. p. 562–99.
McEvoy GK. AHFS drug information 2016. Bethesda, Mary-land: American Society of Health-System Pharmacists (ASHP); 2016. p. 498–507.
Ibarra М, Vázquez M, Fagiolino P. Sex Effect on Average Bioe-quivalence. Clin Ther 2017; 39(1): 23–33.
Anderson GD. Sex and racial differences in pharmacological re-sponse: Where is the evidence? Pharmacogenetics, pharmaco-kinetics, and pharmacodynamics. J Womens Health (Larchmt) 2005; 14(1): 19–29.
Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2009; 48(3): 143–57.
Van Peer A, Woestenborghs R, Heykants J, Gasparini R, Gauwen-bergh G. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol 1989; 36(4): 423–6.
Puttick MP, Phillips P. Itraconazole: Precautions regarding drug interactions and bioavailability. Can J Infect Dis 1994; 5(4): 179–83.
Zimmermann T, Yeates RA, Laufen H, Pfaff G, Wildfeuer A. In-fluence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol 1994; 46(2): 147–50.
Van de Velde VJ, Van Peer AP, Heykants JJ, Woestenborghs RJ, Van Rooy P, De Beule KL, et al. Effect of food on the pharma-cokinetics of a new hydroxypropyl-beta-cyclodextrin formula-tion of itraconazole. Pharmacotherapy 1996; 16(3): 424–8.
Cartledge JD, Midgely J, Gazzard BG. Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodefi-ciency syndrome patients with candidiosis. J Clin Pathol 1997; 50(6): 477–80.
Abdel-Rahman SM, Jacobs RF, Massarella J, Kauffman RE, Brad-ley JS, Kimko HC, et al. Single-dose pharmacokinetics of intra-venous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. Antimicrob Agents Chemother 2007; 51(8): 2668–73.
Abuhelwa AY, Foster DJ, Mudge S, Hayes D, Upton RN. Popula-tion pharmacokinetic modeling of itraconazole and hydroxy-itraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states. An-timicrob Agents Chemother 2015; 59(9): 5681–96.
Czyrski A, Resztak M, Świderski P, Brylak J, Główka FK. The Overview on the Pharmacokinetic and Pharmacodynamic In-teractions of Triazoles. Pharmaceutics 2021; 13(11): 1961.
Bury D, Tissing WJE, Muilwijk EW, Wolfs TFW, Brüggemann RJ. Clinical Pharmacokinetics of Triazoles in Pediatric Pa-tients. Clin Pharmacokinet 2021; 60(9): 1103–47.
Naqvi SMH, Gala MYN, Muchhala S, Arumugam A, Panigrahi D, Patil D, et al. Pharmacokinetics/Pharmacodynamics study of Fixtral SB as compared to supra bioavailable itraconazole and conventional itraconazole. World J Pharmacol 2023; 12(1): 1–11.
Miljković MN, Rančić N, Kovačević A, Cikota-Aleksić B, Skadrić I, Jaćević V, et al. Influence of Gender, Body Mass Index, and Age on the Pharmacokinetics of Itraconazole in Healthy Sub-jects: Non-Compartmental Versus Compartmental Analysis. Front Pharmacol 2022; 13: 796336.
Yun HY, Baek MS, Park IS, Choi BK, Kwon KI. Comparative analysis of the effects of rice and bread meals on bioavailabil-ity of itraconazole using NONMEM in healthy volunteers. Eur J Clin Pharmacol 2006; 62(12): 1033–9.
Bae SK, Park SJ, Shim EJ, Mun JH, Kim EY, Shin JG, et al. In-creased oral bioavailability of itraconazole and its active me-tabolite, 7-hydroxyitraconazole, when coadministered with a vitamin C beverage in healthy participants. J Clin Pharmacol 2011; 51(3): 444–51.
Prieto Garcia L, Janzén D, Kanebratt KP, Ericsson H, Lennernäs H, Lundahl A. Physiologically based pharmacokinetic model of itraconazole and two of its metabolites to improve the predic-tions and the mechanistic understanding of CYP3A4 drug-drug interactions. Drug Metab Dispos 2018; 46(10): 1420–33.
Thummel K, Shen D, Isoherranen N. Design and Optimization of Dosage Regimens: Pharmacokinetic Data. In: Brunton LL, Hi-lal-Dandan R, Knollman BC. Goodman and Gilman’s The Pharmacological Basis of therapeutics. 13th ed. New York: McGraw-Hill Education; 2018. p. 1325–78.
Nakamura Y, Matsumoto K, Sato A, Morita K. Effective plasma concentrations of itraconazole and its active metabolite for the treatment of pulmonary aspergillosis. J Infect Chemother 2020; 26(2): 170–4.
Patni AK, Monif T, Khuroo AH, Tiwary AK. Validated Liquid chromatography tandem mass spectrometric method for quan-tification of Itraconazole and Hydroxy Itraconazole in human plasma for pharmacokinetic study. Der Pharmacia Lettre 2010; 2(2): 41–53.
Liu F, Yi H, Wang L, Cheng Z, Zhang G. A novel method to estimate the absorption rate constant for two compartment model fitted drugs without intravenous pharmacokinetic data. Front. Pharmacol 2023; 14: 1087913.
Ben Mansour G, Kacem A, Ishak M, Grélot L, Ftaiti F. The ef-fect of body composition on strength and power in male and female students. BMC Sports Sci Med Rehabil 2021; 13(1): 150.
Bredella MA. Sex Differences in Body Composition. In: Mau-vais-Jarvis F, editor. Sex and Gender Factors Affecting Meta-bolic Homeostasis, Diabetes and Obesity. Advances in Exper-imental Medicine and Biology, vol 1043. New York: Springer; 2017. p. 9–27.
Karastergiou K, Smith SR, Greenberg AS, Fried SK. Sex differ-ences in human adipose tissues - the biology of pear shape. Bi-ol Sex Differ 2012; 3(1): 13.
Shargel L, Wu-Pong S, Yu A. Applied biopharmaceutics & pharmacokinetics. 6th ed. New York: The McGraw-Hill Companies; 2012. p. 811.
Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmaco-kinetics and pharmacodynamics. Drugs 1995; 50(2): 222–39.
Pollock BG. Gender differences in psychotropic drug metabo-lism. Psychopharmacol Bull 1997; 33(2): 235–41.
Wolbold R, Klein K, Burk O, Nüssler AK, Neuhaus P, Eichelbaum M, et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 2003; 38(4): 978–88.
Sakuma T, Kawasaki Y, Jarukamjorn K, Nemoto N. Sex differ-ences of drug-metabolizing enzyme: Female Predominant Ex-pression of Human and Mouse Cytochrome P450 3A Isoforms. J Health Sci 2009; 55(3): 325–37.
Waxman DJ, O’Connor C. Growth hormone regulation of sex-dependent liver gene expression. Mol Endocrinol 2006; 20(11): 2613–29.
Jaffe CA, Turgeon DK, Lown K, Demott-Friberg R, Watkins PB. Growth hormone secretion pattern is an independent regula-tor of growth hormone actions in humans. Am J Physiol En-docrinol Metab 2002; 283(5): E1008–15.
Yáñez JA, Remsberg CM, Sayre CL, Forrest ML, Davies NM. Flip-flop pharmacokinetics – delivering a reversal of disposi-tion: challenges and opportunities during drug development. Ther Deliv 2011; 2(5): 643–72.
Dvorchik BH, Vessell ES. Significance of error associated with use of the one-compartment formula to calculate clearance of thirty-eight drugs. Clin Pharmacol Ther 1978; 23(6): 617–23.
Loughnan PM, Sitar DS, Ogilvie RI, Neims AH. The two-compartment open-system kinetic model: A review of its clin-ical implications and applications. J Pediatr 1976; 88(5): 869–73.
Wagner JG. Application of the Wagner-Nelson absorption method to the two-compartment open model. J Pharmacoki-net Biopharm 1974; 2(6): 469–86.
Qusai U, Hameed A, Hameed Rasheed K. Compartmental and Non-Compartmental Pharmacokinetic Analysis of Extended Release Diclofenac Sodium Tablet. NUCEJ 2016; 19(1): 161–5.